<DOC>
	<DOCNO>NCT01559103</DOCNO>
	<brief_summary>Study assess safety tolerability MEDI5117 Rheumatoid Arthritis patient</brief_summary>
	<brief_title>Study Assess Safety Tolerability MEDI5117 Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>A Double-blind , Placebo-controlled , Randomized Study Rheumatoid Arthritis Subjects Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Single Ascending Doses MEDI5117 ( anti-IL-6 )</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Active Rheumatoid Arthritis ( RA ) 6 month . Males nonpregnant , nonlactating femails age 20 75 year , inclusive . Body Mass Index ( BMI ) 19 36 kg/m2 weight 50 145 kg , inclusive . Males , unless surgically sterile , must use 2 effective method birth control Day 1 followup . History presence clinically significant disease disorder stable previous 3 month . History liver disease , bilirubin elevation , Gilbert 's Syndrome . Any systematic inflammatory condition addition RA ( polymyalgia rheumatica , giant cell arthritis , systemic lupus , gout , pyrophosphate arthropathy ) . Current , chronic pain disorder include fibromyalgia chronic regional pain syndrome chronic fatigue syndrome . Intramuscular steroid injection intraarticular steroid injection within 1 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Phase I</keyword>
	<keyword>Biologic</keyword>
</DOC>